AI Article Synopsis
- The study investigates how ALCAM (CD166) expression relates to tamoxifen resistance in ER+ breast cancer, finding that higher ALCAM levels are linked to non-responders.
- ALCAM overexpression helps TamS MCF-7 cells resist tamoxifen-induced cell death, while knocking down ALCAM increases cell death in resistant cells.
- MiR-148a and miR-152 can reduce ALCAM levels, suggesting they play a role in making TamR MCF-7 cells more sensitive to tamoxifen treatment.
Article Abstract
Activated leukocyte cell adhesion molecule (ALCAM), also called CD166 is a 105-kDa transmembrane glycoprotein of the immunoglobin superfamily. In this study, we studied the association between ALCAM expression and tamoxifen resistance in ER + breast cancer and further investigated how ALCAM is regulated in the cancer cells. IHC staining data showed that the tumor tissues from non-responders (N = 20) generally had significantly stronger ALCAM staining than that from tamoxifen responders (N = 16). In vitro cell assay also confirmed ALCAM upregulation in tamoxifen resistant (TamR) MCF-7 cells than in tamoxifen sensitive (TamS) MCF-7 cells. ALCAM overexpression significantly alleviated 4-Hydroxytestosterone (4-OHT) induced cell viability inhibition and cell apoptosis in TamS MCF-7 cells, while ALCAM knockdown remarkably enhanced 4-OHT induced cell viability inhibition and cell apoptosis in TamR MCF-7 cells. Demethylation reagent treatment significantly restored miR-148a and miR-152 expression in TamR MCF-7 cells. MiR-148a and miR-152 can directly target ALCAM 3'UTR and decrease ALCAM expression. MiR-148a overexpression had similar effect as ALCAM siRNA on enhancing 4-OHT induced cell viability inhibition and cell apoptosis in TamR MCF-7 cells. MiR-152 overexpression alone caused growth inhibition and increased cell apoptosis in TamR MCF-7 cells. It also enhanced the effect of 4-OHT. Simultaneous inhibition of miR-148a and miR-152 significantly protected TamS MCF-7 cells from 4-OHT induced cell viability inhibition and cell apoptosis. Based on these findings, we infer that MiR-148a and miR-152 can sensitize TamR MCF-7 cells to tamoxifen at least via downregulating ALCAM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2017.01.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradation.
Oncogene
December 2024
Shantou Key Laboratory of Precision Diagnosis and Treatment in Women's Cancer, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Article Synopsis
- - Approximately 70% of breast cancer cases are luminal-type (ER+), which can be treated with tamoxifen, but 30% of these patients develop resistance, mainly due to the activation of the PI3K pathway.
- - Research found that N6 adenine-specific DNA methyltransferase 1 (N6AMT1) is highly expressed in luminal breast cancer but decreased in tamoxifen-resistant cells, with FOXA1 promoting N6AMT1 transcription.
- - Increasing N6AMT1 expression restores tamoxifen sensitivity in resistant cells, and combining tamoxifen with a p110α inhibitor enhances treatment effectiveness, suggesting that N6AMT1 could serve as a biomarker
Synergistic Anti-Tumor Effects of Newcastle Disease Virus and Doxorubicin: Evidence from A Murine Breast Cancer Model.
Int Immunopharmacol
December 2024
Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Academic Center for Education, Culture and Research (ACECR), Motamed Cancer Institute, Tehran, Iran. Electronic address:
Background: Despite the recent advances in the diagnosis and treatment of breast cancer, triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature and resistance to conventional therapies. Virotherapy has emerged as a promising cancer treatment strategy, leveraging the ability of viruses to specifically target and replicate in cancerous cells. This study evaluated the oncolytic potential of a combined therapeutic strategy, utilizing Newcastle disease virus (NDV) and Doxorubicin hydrochloride (Dox) both in vitro and in vivo.
View Article and Find Full Text PDFPPARγ antagonism as a new tool for preventing or overcoming endocrine resistance in luminal A breast cancers.
Biomed Pharmacother
November 2024
Department of Clinical and Biological Sciences, University of Turin, Corso Raffaello 30, Turin 10125, Italy. Electronic address:
Purpose: This research investigates the role of PPARγ in the complex molecular events underlying the acquisition of resistance to tamoxifen (Tam) in luminal A breast cancer (BC) cells. Furthermore, it focuses on evaluating the possibility of repurposing Imatinib mesylate, an FDA-approved anticancer agent recently recognized also as a PPARγ antagonist, for the personalized therapy of endocrine-resistant BC with increased PPARγ expression.
Methods: Differential gene expression between parental and Tam-resistant MCF7 cells was assessed by RNA-seq followed by bioinformatics analysis and validation by RT-qPCR.
P53 Status Influences the Anti-proliferative Effect Induced by IFITM1 Inhibition in Estrogen Receptor-positive Breast Cancer Cells.
Cancer Genomics Proteomics
August 2024
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea;
Background/aim: Interferon-induced trans-membrane protein 1 (IFITM1) is known to be involved in breast cancer progression. We aimed to investigate its role in estrogen receptor (ER)-positive breast cancer cells with wild-type p53 and tamoxifen-resistant breast cancer cells.
Materials And Methods: The ER-positive breast cancer cell lines, MCF-7 with wild-type p53 and T47D with mutant p53, were used.
Unveiling the Correlation Between the Membrane Assembly of P-gp and Drug Resistance in Multiple Myeloma Using Super-Resolution Fluorescence Imaging.
Anal Chem
July 2024
State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, Jilin 130022, China.
Article Synopsis
- Drug resistance in multiple myeloma (MM) is significantly influenced by the dysfunction of P-glycoprotein (P-gp), and this study investigates its spatial organization to better understand its role in treatment resistance.
- Using advanced imaging techniques, the research found that drug-resistant MM cells (MM1R) have a greater clustering of P-gp on their surfaces compared to drug-sensitive cells (MM1S), especially under low oxygen (hypoxic) conditions.
- The study also highlighted that changes in P-gp clustering, influenced by membrane carbohydrates and treatments like dexamethasone, can potentially modulate drug responsiveness, providing new avenues for improving treatment strategies in MM.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!